Barclays’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.44B Buy
1,563,625
+159,958
+11% +$162M 0.35% 33
2025
Q4
$1.51B Sell
1,403,667
-107,091
-7% -$102M 0.36% 32
2025
Q3
$1.15B Buy
1,510,758
+6,359
+0.4% +$4.73M 0.25% 49
2025
Q2
$1.17B Sell
1,504,399
-269,968
-15% -$210M 0.27% 40
2025
Q1
$1.47B Buy
1,774,367
+205,156
+13% +$171M 0.42% 26
2024
Q4
$1.21B Buy
1,569,211
+7,325
+0.5% +$6.07M 0.34% 32
2024
Q3
$1.38B Sell
1,561,886
-506,845
-25% -$456M 0.37% 25
2024
Q2
$1.87B Sell
2,068,731
-38,166
-2% -$30.5M 0.57% 20
2024
Q1
$1.64B Sell
2,106,897
-484,394
-19% -$345M 0.57% 25
2023
Q4
$1.51B Buy
2,591,291
+526,547
+26% +$307M 0.55% 22
2023
Q3
$1.11B Buy
2,064,744
+549,719
+36% +$283M 0.69% 16
2023
Q2
$711M Buy
1,515,025
+905,548
+149% +$380M 0.45% 41
2023
Q1
$209M Sell
609,477
-909,465
-60% -$307M 0.1% 132
2022
Q4
$556M Buy
1,518,942
+366,307
+32% +$130M 0.25% 52
2022
Q3
$373M Buy
1,152,635
+320,937
+39% +$102M 0.41% 40
2022
Q2
$270M Sell
831,698
-356,733
-30% -$107M 0.16% 87
2022
Q1
$340M Sell
1,188,431
-1,583,991
-57% -$408M 0.27% 78
2021
Q4
$766M Buy
2,772,422
+877,346
+46% +$222M 0.29% 65
2021
Q3
$438M Buy
1,895,076
+693,851
+58% +$171M 0.2% 79
2021
Q2
$276M Buy
1,201,225
+143,363
+14% +$28.8M 0.13% 122
2021
Q1
$198M Buy
1,057,862
+202,620
+24% +$39.6M 0.11% 153
2020
Q4
$144M Buy
855,242
+24,139
+3% +$3.6M 0.08% 201
2020
Q3
$123M Buy
831,103
+215,157
+35% +$33.3M 0.07% 189
2020
Q2
$101M Sell
615,946
-179,319
-23% -$27.5M 0.08% 191
2020
Q1
$110M Sell
795,265
-560,737
-41% -$77M 0.09% 146
2019
Q4
$178M Sell
1,356,002
-158,534
-10% -$18.4M 0.1% 162
2019
Q3
$169M Sell
1,514,536
-103,660
-6% -$11.5M 0.11% 151
2019
Q2
$179M Buy
1,618,196
+382,464
+31% +$45M 0.11% 156
2019
Q1
$160M Buy
1,235,732
+198,970
+19% +$24.2M 0.11% 147
2018
Q4
$120M Sell
1,036,762
-322,708
-24% -$36M 0.09% 152
2018
Q3
$146M Buy
1,359,470
+84,369
+7% +$8.43M 0.1% 148
2018
Q2
$109M Sell
1,275,101
-267,103
-17% -$21.9M 0.09% 177
2018
Q1
$119M Buy
1,542,204
+429,605
+39% +$34.6M 0.09% 184
2017
Q4
$94M Buy
1,112,599
+561,514
+102% +$47.8M 0.08% 211
2017
Q3
$47.1M Buy
551,085
+42,554
+8% +$3.49M 0.05% 315
2017
Q2
$41.9M Sell
508,531
-569,873
-53% -$46.5M 0.04% 329
2017
Q1
$90.7M Buy
1,078,404
+317,582
+42% +$25.4M 0.1% 155
2016
Q4
$56M Sell
760,822
-668,566
-47% -$49.8M 0.06% 252
2016
Q3
$115M Buy
1,429,388
+798,310
+126% +$63.9M 0.13% 119
2016
Q2
$49.7M Buy
631,078
+12,685
+2% +$955K 0.06% 257
2016
Q1
$44.5M Sell
618,393
-22,446
-4% -$1.7M 0.07% 247
2015
Q4
$53.8M Sell
640,839
-85,072
-12% -$7.06M 0.07% 256
2015
Q3
$60.3M Sell
725,911
-391,473
-35% -$33M 0.07% 229
2015
Q2
$92.7M Sell
1,117,384
-382,978
-26% -$29.2M 0.1% 158
2015
Q1
$108M Buy
1,500,362
+56,114
+4% +$3.99M 0.12% 142
2014
Q4
$98.2M Buy
1,444,248
+174,714
+14% +$11.8M 0.09% 170
2014
Q3
$81.3M Sell
1,269,534
-66,566
-5% -$4.21M 0.08% 203
2014
Q2
$82.8M Sell
1,336,100
-122,478
-8% -$7.31M 0.09% 183
2014
Q1
$84.6M Sell
1,458,578
-412,183
-22% -$23M 0.1% 182
2013
Q4
$95.4M Buy
1,870,761
+62,096
+3% +$3.11M 0.1% 167
2013
Q3
$90.4M Buy
1,808,665
+180,274
+11% +$9.44M 0.11% 141
2013
Q2
$80M Buy
+1,628,391
New +$88.6M 0.1% 150

Other funds holding LLY

Barclays's LLY Position: Q1 2026 in Review

Barclays increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $162M and bringing the position to 1,563,625 shares worth $1.44B. The position accounts for 0.35% of the portfolio, ranked #33.

Barclays first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.87B in Q2 2024. 4,363 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Barclays held 1,563,625 shares of Eli Lilly worth $1.44B as of Q1 2026.
  • Barclays bought 159,958 Eli Lilly shares in Q1 2026, an estimated $162M.
  • Eli Lilly made up 0.35% of Barclays's portfolio in Q1 2026, its #33 holding.
  • Barclays first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Eli Lilly position peaked at $1.87B in Q2 2024.
  • 4,363 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.